Results for tag: "Wilms Tumor Protein"

The Wilms Tumor Protein (WT1) is a protein that is expressed in Wilms tumors, a type of cancer that affects the kidneys. WT1 is a promising target for the development of oncology drugs, as it is involved in the regulation of cell growth and differentiation. WT1-targeted therapies have the potential to be used in combination with other treatments, such as chemotherapy and radiation, to improve outcomes for patients with Wilms tumors. Several companies are developing WT1-targeted therapies for the treatment of Wilms tumors. These include Novartis, which is developing a WT1-targeted antibody-drug conjugate, and Merck, which is developing a WT1-targeted small molecule. Other companies, such as AstraZeneca and Pfizer, are also researching WT1-targeted therapies. Show Less Read more